Amgen Inc.

- The call does not mention any current or planned new fundraising through debt or equity. - In Q1, Amgen incurred $480 million of non-GAAP OI&E expenses, including a $90 million gain from retiring debt via open market repurchases, indicating some debt reduction activity. - The company expects share repurchases not to exceed $3 billion in 2026, showing capital return to shareholders rather than equity issuance. - Guidance does not include any potential business development transactions that may occur in the remainder of the year, but no explicit mention of raising capital. - Overall, Amgen appears focused on investing internal cash flow and managing existing financial obligations without announcing new debt or equity fundraising in this call.

- Amgen invested $700 million in capital expenditures in Q1 2026, focused on U.S. manufacturing sites in Ohio, North Carolina, and Puerto Rico. - Full-year 2026 capital expenditures are expected to be approximately $2.6 billion. - These investments aim to scale manufacturing capacity to support volume growth, including for the upcoming launch of MariTide. - The company continues to invest significantly in advancing its late-stage pipeline, including MariTide, IMDELLTRA, and Olpasiran. - Emphasis on technology and AI to enhance productivity and operational efficiency across the enterprise, such as AI reducing production line clearance from 30 to 2 minutes per batch. - Continued investment in innovation and clinical development aligns with long-term growth and strategic objectives.

- Amgen expects 2026 to be a "springboard year" for future growth, with rapidly growing products offsetting patent expirations and competition. - Guidance for 2026 revenue raised to $37.1 billion to $38.5 billion. - Non-GAAP earnings per share guidance raised to $21.70 to $23.10. - Six key growth drivers (including Repatha, EVENITY, TEZSPIRE, rare disease, innovative oncology, biosimilars) generated 70% of sales and grew 24% year-over-year. - Biosimilars have generated more than $14 billion cumulatively since 2018, contributing meaningful growth and expanding patient access. - Continued investment in pipeline, particularly MariTide, IMDELLTRA, and Olpasiran, with increased R&D spending by 16% year-over-year. - Strong first quarter performance with free cash flow of $1.5 billion and product sales growth of 4%. - Innovation pipeline and AI integration expected to deliver sustained long-term growth.

- Amgen expects 2026 to be a "springboard year" for future growth, driven by rapidly growing products offsetting patent expirations and competition. - Raised 2026 guidance ranges for revenue ($37.1B to $38.5B) and non-GAAP earnings per share (EPS) between $21.70 and $23.10. - Non-GAAP operating margin for 2026 is expected to be roughly 45% to 46% of product sales, consistent with Q1 performance. - Non-GAAP operating income and expenses projected at $2.2B to $2.3B for 2026. - Non-GAAP tax rate expected in the range of 15.0% to 16.5%. - Free cash flow showed $1.5 billion in Q1, supporting continued investments and shareholder returns. - Investments in pipeline innovation and manufacturing capacity (including for MariTide launch) prioritized to sustain long-term growth.

The provided document does not contain specific information on current or expected orderbook or pending orders for Amgen. The focus is primarily on: - Clinical trial updates (e.g., MariTide studies, IMDELLTRA trials) - Financial performance and guidance for 2026 - Product launches and market adoption (MariTide, IMDELLTRA, Repatha, EVENITY) - AI integration and manufacturing improvements - Regulatory and tax litigation status - Leadership changes and strategic focus areas No explicit data or commentary on orderbook volumes or pending orders is disclosed in the selected pages.